Hypoxia-inducible factor-1α and hypoxia-inducible factor-2α are expressed in Kaposi sarcoma and modulated by insulin-like growth factor-I

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4506-4514

  Catrina, Sergiu Bogdan ^a   Botusan, Ileana Ruxandra ^a   Rantanen, Anja ^a   Catrina, Anca Irinel ^a   Pyakurel, Pawan ^a   Savu, Octavian ^a   Axelson, Magnus ^a   Biberfeld, Peter ^a   Poellinger, Lorenz ^b   Brismar, Kerstin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHAIR 3; PICROPODOPHYLLIN; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPOSI SARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY, NEEDLE; CELL HYPOXIA; COBALT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; PODOPHYLLOTOXIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33748042960     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2473     Document Type: Article

References (51)

1. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
2. Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
3. 2-regulated prolyl hydroxylation. Science 2001;292:468-72
4. Epstein AC, Gleadle JM, McNeill LA, et al. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
5. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002;99:13459-64.
6. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-61.
7. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney: suppression of HIF-mediated gene expression by HIF-3α. Biochem Biophys Res Commun 2001;287:808-13.
8. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4.
9. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3α locus. J Biol Chem 2002;277:32405-8.
10. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997;94:4273-8.
11. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
12. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor lain brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88:2606-18.
13. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 1997;94:979-84.
14. Cornali E, Zietz C, Benelli R, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996;149:1851-69.
15. Chor PJ, Santa Cruz DJ. Kaposi's sarcoma. A clinicopathologic review and differential diagnosis. J Cutan Pathol 1992;19:6-20.
16. Catrina SB, Lewitt M, Massambu C, et al. Insulin-like growth factor-1 receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer 2005;92:1467-74.
17. Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouel-Kartmann MN, Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Mol Endocrinol 2005;19:1304-17.
18. Akeno N, Robins J, Zhang M, Czyzyk-Krzeska MF, Clemens TL. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2a. Endocrinology 2002;143:420-5.
19. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinasesignaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
20. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42.
21. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004;53:3226-32.
22. Bookout AL, Cummins CL, Mangelsdorf DJ. High-throughput real-time quantitative reverse transcription PCR. In: Ausubel FMR, Brent RE, Kingston DD, Moore JG, Seidman JA, Smith, Struhl K, editors. Current protocols in molecular biology. New York: John Wiley & Sons, Inc.: 2005. p. 15.18.11-15.18.21.
23. Albini A, Paglieri I, Orengo G, et al. The β-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 1997;11:713-21.
24. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
25. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-1: definition of regulatory domains within the α subunit. J Biol Chem 1997;272:11205-14.
26. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610-5.
27. Obrig TG, Culp WJ, McKeehan WL, Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 1971;246:174-81.
28. Flier JS, Usher P, Moses AC. Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts. Proc Natl Acad Sci U S A 1986;83:664-8.
29. Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994;86:1711-6.
30. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-11.
31. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999;13:2563-70.
32. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
33. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411 -21.
34. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
35. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
36. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
37. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
38. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. BioEssays 2004;26:262-9.
39. Wang V, Davis DA, Hague M, Huang LE, Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1 aand hypoxia-inducible factor-2α in HEK293T cells. Cancer Res 2005;65:3299-306.
40. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
41. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
42. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-55.
43. Kaaya E, Castanos-Velez E, Heiden T, et al. Proliferation and apoptosis in the evolution of endemic and acquired immunodeficiency syndrome-related Kaposi's sarcoma. Med Oncol 2000;17:325-32.
44. Ensoli B, Sturzl M, Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv Cancer Res 2001;81:161-200.
45. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1α Cancer Res 2000;60:4873-80.
46. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999;59:3915-8.
47. Kimball SR, Farrell PA, Jefferson LS. Invited Review: Role of insulin in translational control of protein synthesis in skeletal muscle by amino acids or exercise. J Appl Physiol 2002;93:1168-80.
48. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
49. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 α nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 2002;277:15162-70.
50. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-25.
51. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.